A new international study protocol, published by the World Health Organization (WHO) in 2025, lays the groundwork for a critical public health initiative: determining how often a rare blood disorder occurs in children across low- and middle-income countries (LMICs). The study focuses on thrombocytopenia—a condition characterized by abnormally low platelet counts that can lead to bruising and bleeding.
This research is not about investigating a current outbreak. Instead, it is a proactive step to establish essential background rates. These baseline figures are crucial for future vaccine safety monitoring, providing a reference point to distinguish between coincidental illnesses and potential side effects when new vaccines are introduced to millions of children.
The Critical Need for Baseline Data
The protocol identifies a significant gap in global health data. While thrombocytopenia is a known but very rare adverse event of special interest (AESI) associated with some vaccines like the measles-mumps-rubella (MMR) vaccine, reliable data on how often it occurs naturally in children in LMICs is scarce.
This lack of a baseline is a major challenge for pharmacovigilance—the science of monitoring medicine safety. Without knowing the expected background rate, it is difficult for health authorities to determine if cases reported after a vaccination campaign represent a genuine safety signal or are merely coincidental.
The urgency for this data is amplified by the anticipated rollout of new vaccines, such as the R21 Malaria vaccine and new dengue vaccines, across LMICs in the coming years. By establishing background rates now, the study will equip national regulators with the evidence needed to make swift, accurate safety assessments post-introduction.
Study Design: A Multinational Observational Approach
The protocol outlines a multisite, prospective observational study to be conducted in sentinel health facilities across multiple LMICs.
- Core Methodology: Researchers will identify and enroll children aged 5 months to under 15 years who are admitted to participating hospitals with suspected or confirmed thrombocytopenia. The diagnosis will be standardized using the internationally recognized Brighton Collaboration case definition, which classifies cases by levels of diagnostic certainty based on platelet counts and clinical signs.
- Calculating the Rate: A key innovation is the method for calculating the “at-risk” population, or denominator. Since following millions of children prospectively is not feasible, the study will use national census data and sophisticated geographic mapping to estimate the population size served by each hospital (its catchment area), accounting for travel time and distance.
- Primary Objective: The main goal is to calculate the annual background incidence rate of all-cause thrombocytopenia (cases per 100,000 person-years).
- Secondary Objective: The study will also estimate the rate of thrombocytopenia occurring after any recent vaccination (within 42 days), which will provide valuable context for vaccine safety profiles.
Rigorous Ethics and Standardized Implementation
The document is a master protocol, approved by the WHO Research Ethics Review Committee. It is designed to ensure consistency and high ethical standards across all participating countries, which will adapt it for local approval.
Key ethical and operational pillars include:
- Informed Consent: Mandatory informed assent from children (aged 8+) and consent from their parents or guardians.
- Data Confidentiality and Security: A strong emphasis on data protection. All data will be de-identified, and secure electronic systems will be used for collection and storage, complying with standards like the GDPR.
- Capacity Building: The study is designed to strengthen local systems. The data capture technology and training provided will remain at the study sites to improve sustainable vaccine safety surveillance long after the project ends.
Acknowledging Limitations and Looking Ahead
The protocol thoughtfully addresses inherent challenges, such as potential inaccuracies in population estimates, the reliance on self-reported vaccination history (which can lead to recall bias), and the fact that participating hospitals with better diagnostics may not fully represent entire national populations.
Despite these limitations, the initiative represents a major advance in global health security. It moves vaccine safety monitoring in LMICs from a reactive to a proactive model. The data generated will create a foundational evidence base, enabling more confident and science-driven decisions about the lifesaving vaccines of today and tomorrow.
Conclusion
The WHO’s thrombocytopenia background rate protocol is more than a research study; it is an investment in the future of vaccine safety. By systematically gathering this essential baseline data, the global health community is working to ensure that the trust in immunization programs—one of public health’s most powerful tools—is maintained and strengthened through rigorous, transparent science.
